Clinical trials: Graft -Versus-host-disease
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 3, 2-arm, randomized, open label trial. Patients will be randomized to receive bosutinib or imatinib for the duration of the study.
- Trial name
- NCT02130557
- Testing
- Bosutinib, Imatinib
- Where
- 189 sites in United States, Australia and 24 more
- Volunteers
- 536 people
- Sponsor
- Pfizer
Dry Eye Disease, oGVHD
2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD
Evaluate and study the immunologic changes to the ocular surface in cancer patients.
- Trial name
- NCT04946721
- Testing
- The standard care exam and biological specimens' collection
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Graft-Versus-Host Disease
Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis
The main aim is to test the preventive use of extracorporeal photophoresis (ECP) against development of graft-versus-host disease (GVHD) in patients undergoing allogeneic stem cell transplantation for hematological malignancy.
- Trial name
- GVHD (NCT03204721)
- Testing
- Extracorporeal photophoresis (ECP)
- Where
- Norway
- Volunteers
- 158 people
- Sponsor
- Oslo University Hospital
Graft-vs-Host Disease
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD).
- Trial name
- NCT00032279
- Testing
- Visilizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Mastocytosis
Stem Cell Transplantation to Treat Systemic Mastocytosis
This study will investigate the safety and effectiveness of an experimental stem cell transplant procedure for treating mastocytosis-a disease of abnormal mast cell growth.
- Trial name
- NCT00006413
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Psoriasis
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
The main objective of this study is to evaluate the long term safety of CP-690,550 in patients being treated for moderate to severe plaque psoriasis and/or psoriatic arthritis.
- Trial name
- NCT01519089
- Testing
- CP-690,550, CP-690, 550
- Where
- 16 sites in Japan
- Volunteers
- 95 people
- Sponsor
- Pfizer
Graft Versus Host Disease
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD).
- Trial name
- NCT00529035
- Testing
- Interleukin-2
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Hematopoietic Stem Cell Transplantation, Multiple Myeloma
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Allogeneic hematopoietic stem cell transplantation (HTC) is the only curative option for many patients with hematologic malignancies but >50% of this patients will develop extensive chronic graft-versus-host disease (cGVHD)…
- Trial name
- NCT03225417
- Testing
- Ixazomib, Tacrolimus, Sirolimus
- Where
- 8 sites in Spain
- Volunteers
- 142 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Traumatic Brain Injury
Safety Study of Umbilical Cord Blood To Treat Pediatric Traumatic Brain Injury
The purpose of this study is to determine if it is safe to use stored autologous Human Umbilical Cord Blood (hUCB) to treat pediatric patients that sustain a severe or moderate Traumatic Brain Injury (TBI), and have not fully…
- Trial name
- NCT01251003
- Testing
- Autologous cord blood
- Where
- United States
- Sponsor
- Charles Cox
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Chronic Graft-versus-host Disease
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Alefacept is a drug tht may reduce the number of T cells in circulation. This drug has been used in the treatment of psoriasis, which is a skin disorder also caused by T cells, like chronic GVHD.
- Trial name
- NCT01226420
- Testing
- Alefacept
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease (cGvHD)
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well.
- Trial name
- EVENT (NCT06991361)
- Testing
- EVE-Treg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sarah Nikiforow, MD
Acute-graft-versus-host Disease
Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease
This is a single arm phase 2 trial which includes patients with high risk acute GVHD defined as Ann Arbor score 2 or 3. The purpose of the study is to improve the outcome of these patients in terms of response to treatment and…
- Trial name
- NCT04291261
- Testing
- Uvadex
- Where
- 4 sites in Austria, Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Hematopoietic Stem Cell Transplantation, Graft Versus Host Disease
Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation
The purpose of this trial is to assess whether an adaptation of cyclosporine (CsA) dose according to a longitudinal calcineurin (CN) activity monitoring would prevent the onset of graft-versus-host disease (GVHD).
- Trial name
- CALCICLO (NCT00948727)
- Testing
- Dose adaptation according to CN activity monitoring, Cyclosporine (CsA)
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Graft vs Host Disease
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
A Phase IIa single arm open-label study to investigate the safety, tolerability, and PK of F-652 in combination with systemic corticosteroids in subjects who have undergone Hematopoietic Stem Cell Transplantation (HSCT) and have…
- Trial name
- NCT02406651
- Testing
- Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- EVIVE Biotechnology
Chagas' Disease (Chronic) Nos
Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
This study focuses on the evaluation of low doses (600 and 1200 mg) and short treatment duration (at 3, 7 and 10 days) of fexinidazole (Fexi) to determine the minimal efficacious and safe dose for the treatment of adult patients…
- Trial name
- FEXI12 (NCT03587766)
- Testing
- Fexinidazole
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Drugs for Neglected Diseases
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00053157
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Acute Graft Versus Host Disease
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBT
To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with malignant hematologic diseases after single-unit unrelated cord blood transplantation (sUCBT).
- Trial name
- NCT07047456
- Testing
- Time of umbilical cord blood infusion
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Anhui Provincial Hospital
Liver Transplantation, Graft Versus Host Disease
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
The aim of this research is to design a randomized controlled clinical study, which is based on HLA matching rate to guide tacrolimus regimen.
- Conditions
- Liver Transplantation, Graft Versus Host Disease, Graft Rejection, Drug-Related Side Effects and Adverse Reactions
- Trial name
- NCT03147157
- Testing
- tacrolimus regimen guided by HLA matching rate
- Volunteers
- 120 people
- Sponsor
- The First Hospital of Jilin University
Hematopoietic Stem Cell Transplantation
Lymphocyte Count, ATG Dose and Incidence and Severity of GVHD in Pediatric Recipients of HSCT
Despite increasing success rate in hematopoietic stem cell transplantation (HSCT) control of graft versus host disease (GVHD) remains a significative burden in mortality and morbidity.
- Trial name
- NCT04869254
- Testing
- Lower lymphocyte/ATG ratio, Higher lymphocyte/ATG ratio
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- IRCCS Burlo Garofolo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.